KRAS and non-small cell lung carcinoma: Since KRAS as one of the most frequently mutated oncogenes, it is mutated in approximately 25% of all human cancers, participating in more than 90% of pancreatic ductal adenocarcinomas (PDAC), approximately 30–40% of colon cancers (CRC), and 17% of non-small cell lung cancer (NSCLC) [3].